<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02026778</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0691</org_study_id>
    <nct_id>NCT02026778</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients undergoing gynecologic laparoscopic surgery experience postoperative nausea
      and vomiting (PONV) despite prophylaxis and treatment with HT3 receptor antagonists such as
      ondansetron. Involvement of multiple types of receptors and factors may be a reason for
      inadequate control of PONV with a single agent. Betahistine, a histamine antagonist at H1
      receptor and antagonist at H3 receptor, is widely used as a treatment of dizziness.
      Dizziness is one of the cause of nausea and vomiting. This study is to compare the effects
      of ondansetron and combined ondansetron and betahistine in preventing PONV in high-risk
      patients receiving intravenous opioid-based patient-controlled analgesia (IV-PCA) after
      gynecological laparoscopic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>at postoperative 24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation of nausea and vomiting with verbal rating scale (VRS, 0, no nausea; 10, worst imaginable nausea)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>ondansetron-betahistine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ondansetron-betahistine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ondansetron group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>The ondansetron group is given placebo (pyridoxin) instead of betahistine.
The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.</description>
    <arm_group_label>ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron-betahistine</intervention_name>
    <description>The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.
The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.</description>
    <arm_group_label>ondansetron-betahistine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient scheduled for elective gynecological laparoscopic surgery

          -  American society of Anesthesiologists physical class I, â…¡, between the ages of 20 and
             70 years

        Exclusion Criteria:

          -  hepatorenal disease

          -  BMI &gt; 35 kg/m2

          -  allergy to ondansetron or betahistine

          -  gastrointestinal disease

          -  vomiting within 24h

          -  administration of antiemetics or opioids within 24h

          -  QT prolongation (QTc &gt; 440ms)

          -  Pheochromocytoma

          -  pregnant

          -  problem with communication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bon Nyeo Koo, MD</last_name>
    <phone>82-2-2228-2420</phone>
    <email>koobn@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon Nyeo Koo, MD</last_name>
      <phone>82-2-2227-7897</phone>
      <email>koobn@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betahistine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
